PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1986 August; 79(8): 451–453.
PMCID: PMC1290413

Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.

Abstract

Forty-eight hirsute women were treated with spironolactone 100 mg twice daily for 3 to 12 months. Both facial and body hirsuties improved by 30-40%, and there was a threefold reduction in frequency of local treatments such as waxing or shaving. Plasma testosterone fell by 30%, though the improvement in hirsuties grading did not correlate with the fall in plasma testosterone. Six subjects discontinued treatment because of lack of effect, and 4 because of menstrual disturbance. Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (462K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Coney P. Polycystic ovarian disease: current concepts of pathophysiology and therapy. Fertil Steril. 1984 Nov;42(5):667–682. [PubMed]
  • Spironolactone and endocrine dysfunction. Ann Intern Med. 1976 Nov;85(5):630–636. [PubMed]
  • Ober KP, Hennessy JF. Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med. 1978 Nov;89(5 Pt 1):643–644. [PubMed]
  • Boisselle A, Tremblay RR. New therapeutic approach to the hirsute patient. Fertil Steril. 1979 Sep;32(3):276–279. [PubMed]
  • Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab. 1980 Sep;51(3):429–432. [PubMed]
  • Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA. 1982 Mar 5;247(9):1295–1298. [PubMed]
  • Milewicz A, Silber D, Kirschner MA. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol. 1983 Apr;61(4):429–432. [PubMed]
  • Messina M, Manieri C, Biffignandi P, Massucchetti C, Novi RF, Molinatti GM. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest. 1983 Feb;6(1):23–27. [PubMed]
  • Abramovici Y, Guillet F, Matte R, Chaieb L, Belanger R. La spironolactone dans l'hirsutisme idiopathique, évaluations clinique et biologique du traitement. Ann Endocrinol (Paris) 1983;44(6):393–396. [PubMed]
  • Spandri P, Gangemi M, Nardelli GB, Meneghetti G, Grandesso R, De Salvia D, Ambrosio GB, Predebon O. Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. Clin Exp Obstet Gynecol. 1984;11(1-2):49–54. [PubMed]
  • Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril. 1985 Feb;43(2):200–205. [PubMed]
  • Dorrington-Ward P, McCartney AC, Holland S, Scully J, Carter G, Alaghband-Zadeh J, Wise P. The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol (Oxf) 1985 Aug;23(2):161–167. [PubMed]
  • Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA. 1973 Jul 2;225(1):40–43. [PubMed]
  • Boisselle A, Dionne FT, Tremblay RR. Interaction of spironolactone with rat skin androgen receptor. Can J Biochem. 1979 Jul;57(7):1042–1046. [PubMed]
  • Eil C, Edelson SK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab. 1984 Jul;59(1):51–55. [PubMed]
  • Menard RH, Stripp B, Gillette JR. Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology. 1974 Jun;94(6):1628–1636. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press